Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androstenedone SCHEMBL134061 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL1144460 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL172864 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL12430773 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL14450072 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL10597170 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL4266758 | 0.92 | CYP19A1 (0.84) | CYP19A1CYP3A4LMNA | |
| SCHEMBL6897786 | 0.88 | CYP19A1 (0.79) | CYP19A1CYP3A4LMNAMAPT | |
| SCHEMBL8491921 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP3A4LMNA | |
| SCHEMBL6999301 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227208-B2 | Process for the enantioselective reduction and oxidation, respectively, of steroids | IEP GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227208-B2 | Process for the enantioselective reduction and oxidation, respectively, of steroids | IEP GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| EP-2004838-B1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES BY REDUCTION OF OXOSTEROID COMPOUNDS OR BY OXIDATION OF HYDROXYSTEROID COMPOUNDS USING A HYDROXYSTEROID DEHYDROGENASE | IEP GMBH (DE) | 2012-06-13 | — | — | EP | disclosed |
| EP-1507867-B1 | PROCESS FOR FERMENTATION OF PHYTOSTEROLS TO ANDROSTADIENEDIONE | ORGANON NV (NL) | 2011-08-03 | — | — | EP | disclosed |
| US-20100323390-A1 | Method for the Identification of a Metabolic Pathway Family by Means of Positive Selection | LIBRAGEN (FR) | 2010-12-23 | — | — | US | disclosed |
| US-7846874-B2 | Method for the identification of a metabolic pathway family by means of positive selection | LIBRAGEN (FR) | 2010-12-07 | — | — | US | disclosed |
| US-20090280525-A1 | PROCESS FOR THE ENANTIOSELECTIVE REDUCTION AND OXIDATION, RESPECTIVELY, OF STEROIDS | IEP GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
| US-20090280525-A1 | PROCESS FOR THE ENANTIOSELECTIVE REDUCTION AND OXIDATION, RESPECTIVELY, OF STEROIDS | IEP GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
| EP-1730296-B1 | METHOD FOR THE IDENTIFICATION OF A METABOLIC PATHWAY FAMILY BY MEANS OF POSITIVE SELECTION | LIBRAGEN (FR) | 2009-06-10 | — | — | EP | disclosed |
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-05-28 | — | — | US | disclosed |
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-05-28 | — | — | US | disclosed |
| WO-2007118644-A1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES BY REDUCTION OF OXOSTEROID COMPOUNDS OR BY OXIDATION OF HYDROXYSTEROID COMPOUNDS USING A HYDROXYSTEROID DEHYDROGENASE | IEP GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070184449-A1 | Method for the identification of a metabolic pathway family by means of positive selection | LIBRAGEN (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1730296-A1 | METHOD FOR THE IDENTIFICATION OF A METABOLIC PATHWAY FAMILY BY MEANS OF POSITIVE SELECTION | Libragen (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095634-A1 | METHOD FOR THE IDENTIFICATION OF A METABOLIC PATHWAY FAMILY BY MEANS OF POSITIVE SELECTION | LIBRAGEN (FR) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | NR5A1, NR3C2, CYP17A1 | CYP19A1 13/4885CYP3A4 119/4885LMNA 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.